Cervical Cytology - Bethesda Reporting and HPV Reflex

Key Points

• Cytology category alone no longer determines management; HPV and prior history matter.
• ASC-US, LSIL, ASC-H, HSIL, AGC, and AIS have distinct risk implications.
• HPV16 and HPV18 are particularly high-risk genotypes.
• ASCCP uses immediate and 5-year CIN3+ risk thresholds to guide management.
• ASC-H generally requires colposcopy even if HPV is negative.
• AGC often requires both cervical and endometrial evaluation depending on age and risk.
• Expedited treatment is appropriate only for selected very high-risk nonpregnant patients.
• Patients treated for CIN2+ require long-term surveillance, often for at least 25 years.

Algorithm

1. Confirm patient age, pregnancy status, immune status, current cytology/HPV results, and prior screening or treatment history.
2. Verify specimen adequacy and HPV genotype information.
3. Use the current ASCCP risk calculator or endorsed tables to estimate CIN3+ risk.
4. Perform colposcopy when the calculated risk crosses the action threshold.
5. Use expedited excisional treatment only when criteria are met and shared decision-making supports it.
6. For AGC, add endocervical and selected endometrial sampling.
7. After treatment, follow the dedicated post-treatment surveillance pathway.
8. Return to routine screening only when the risk estimate and history permit.

Clinical Synopsis & Reasoning

Cervical cytology remains an important component of cervical cancer screening and triage. The Bethesda System reports whether the specimen is satisfactory, whether transformation-zone components are present when relevant, and whether epithelial abnormalities involve squamous or glandular cells. Common squamous categories include ASC-US, LSIL, ASC-H, HSIL, and squamous cell carcinoma. Glandular categories include atypical glandular cells, adenocarcinoma in situ, and adenocarcinoma.

A cytology result should be interpreted with HPV testing. High-risk HPV infection is the necessary driver of most cervical precancers and cancers. HPV 16 and 18 carry particularly high risk. Primary HPV screening, cotesting, and cytology-based strategies can all be used within approved age and interval frameworks, but abnormal-result management increasingly relies on risk rather than a rigid one-result algorithm.

Specimen adequacy matters. Unsatisfactory cytology may require repeat testing because absence of abnormal cells cannot be trusted when cellularity is inadequate. Blood, inflammation, atrophy, and poor sampling can obscure interpretation. Presence or absence of transformation-zone cells is reported but does not automatically make an otherwise satisfactory test inadequate. Pregnancy, immunosuppression, age, prior CIN2+, and prior treatment alter management.

Treatment Strategy & Disposition

ASCCP risk-based management uses current results and screening history to estimate immediate and 5-year risk of CIN3+. Patients above the colposcopy threshold proceed to colposcopic evaluation; those at lower but nontrivial risk undergo repeat HPV-based testing at defined intervals. Certain high-risk combinations, such as HPV16-positive HSIL in a nonpregnant patient at least 25 years old, can meet thresholds for expedited excisional treatment without preceding biopsy after shared decision-making.

ASC-US with negative HPV is often low risk, while HPV-positive ASC-US may trigger surveillance or colposcopy depending on prior results. LSIL behaves similarly in modern risk tables. ASC-H generally requires colposcopy regardless of HPV because cancer risk is disproportionately important. AGC requires evaluation beyond simple cervical colposcopy, often including endocervical sampling and, in selected age or risk groups, endometrial sampling.

After treatment for CIN2 or CIN3, patients require prolonged HPV-based surveillance for at least 25 years because risk remains elevated. Do not return a treated patient to routine screening simply because one follow-up test is negative. Screening can usually stop after the recommended age only when prior testing is adequate and there is no history requiring continued surveillance.

Epidemiology / Risk Factors

• Persistent high-risk HPV infection is the central cause of cervical precancer.
• Vaccination has reduced HPV infection and precancer in vaccinated populations.
• Screening incidence and recommended intervals vary with age, prior results, and test strategy.
• Cervical cancer is largely preventable through vaccination, screening, and treatment of precancer.

Investigations

Bethesda Highlights

Pharmacology

Prognosis / Complications

• Most low-grade HPV-related abnormalities regress spontaneously.
• HSIL and persistent HPV16/18 carry greater progression risk.
• Treatment of CIN2/3 substantially reduces cancer risk but does not return risk immediately to baseline.
• Invasive cancer prognosis depends strongly on stage at diagnosis.

Patient Education / Counseling

• Explain that an abnormal Pap does not necessarily mean cancer.
• Tell patients whether HPV was detected and whether a high-risk genotype was identified.
• Provide the exact next step and time frame, such as repeat HPV testing, colposcopy, or treatment.
• Encourage HPV vaccination when age and prior vaccination status make it appropriate; vaccination does not treat an existing lesion but reduces future risk.
• Patients treated for high-grade disease should understand why surveillance continues for many years.

Notes

The biggest conceptual shift is from result-based to risk-based care. Two patients with the same cytology result can appropriately receive different management because their HPV genotype and prior history are different.

A pathology or laboratory article should therefore avoid fixed statements such as 'HPV-positive ASC-US always means colposcopy.' The correct next step comes from the current ASCCP risk framework.

References

1. ASCCP 2019 Risk-Based Management Consensus Guidelines — Link
2. ASCCP Guidelines — Link